Literature DB >> 1615140

Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

N S Gray1, A D Pickering, D R Hemsley, S Dawling, J A Gray.   

Abstract

The performance of healthy volunteer subjects on an auditory latent inhibition (LI) paradigm was assessed following administration of a single oral dose of d-amphetamine or placebo. It was predicted that a low (5 mg), but not a high (10 mg), dose of d-amphetamine would disrupt LI. The prediction was supported with left ear presentation of the preexposed stimulus only. When the preexposed stimulus was presented to the right ear the predicted pattern of findings was not obtained. It is concluded that the dopaminergic system is involved in the mediation of LI in man and it is speculated that the interaction between amphetamine dose and ear of presentation of the preexposed stimulus may reflect normally occurring dopaminergic hemisphere asymmetry.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615140     DOI: 10.1007/bf02245170

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

Review 1.  The dopamine hypothesis of schizophrenia: a review.

Authors:  H Y Meltzer; S M Stahl
Journal:  Schizophr Bull       Date:  1976       Impact factor: 9.306

2.  Facilitation of latent inhibition by haloperidol in rats.

Authors:  I Weiner; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 3.  Latent inhibition.

Authors:  R E Lubow
Journal:  Psychol Bull       Date:  1973-06       Impact factor: 17.737

4.  Amphetamine psychosis: behavioral and biochemical aspects.

Authors:  B Angrist; G Sathananthan; S Wilk; S Gershon
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

5.  Variations in intensity, interstimulus interval, and interval between preconditioning CS exposures and conditioning with rats.

Authors:  C R Crowell; D C Anderson
Journal:  J Comp Physiol Psychol       Date:  1972-05

6.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

7.  Correlation of dose-dependent effects of acute amphetamine administration on behavior and local cerebral metabolism in rats.

Authors:  L J Porrino; G Lucignani; D Dow-Edwards; L Sokoloff
Journal:  Brain Res       Date:  1984-07-30       Impact factor: 3.252

8.  Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine.

Authors:  I Weiner; A Izraeli-Telerant; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder.

Authors:  P R Solomon; A Crider; J W Winkelman; A Turi; R M Kamer; L J Kaplan
Journal:  Biol Psychiatry       Date:  1981-06       Impact factor: 13.382

10.  What have cognitive deficits to do with schizophrenic symptoms?

Authors:  D R Hemsley
Journal:  Br J Psychiatry       Date:  1977-02       Impact factor: 9.319

View more
  31 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

2.  Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man.

Authors:  V Kumari; P J Corr; O F Mulligan; P A Cotter; S A Checkley; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

3.  The visual search analogue of latent inhibition: implications for theories of irrelevant stimulus processing in normal and schizophrenic groups.

Authors:  R E Lubow; Oren Kaplan
Journal:  Psychon Bull Rev       Date:  2005-04

4.  Abnormal latent inhibition and impulsivity in coloboma mice, a model of ADHD.

Authors:  Kristy J Bruno; Christopher S Freet; Robert C Twining; Kiyoshi Egami; Patricia S Grigson; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2006-10-24       Impact factor: 5.996

5.  Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure.

Authors:  M H Joseph; S L Peters; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.

Authors:  L A Dunn; G E Atwater; C D Kilts
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

8.  Catecholaminergic depletion within the prelimbic medial prefrontal cortex enhances latent inhibition.

Authors:  A J D Nelson; K E Thur; C A Marsden; H J Cassaday
Journal:  Neuroscience       Date:  2010-07-07       Impact factor: 3.590

9.  A pre-clinical study showing how dopaminergic drugs administered during pre-exposure can impair or facilitate latent inhibition.

Authors:  N A Schmajuk; J A Gray; J A Larrauri
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

10.  Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

Authors:  Mark D Black; Geoffrey B Varty; Michal Arad; Segev Barak; Amaya De Levie; Denis Boulay; Philippe Pichat; Guy Griebel; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.